肺癌治疗早期临床试验中研究者主观或判断性疗效与毒性报告的使用
该研究评估了2024年美国临床肿瘤学会(ASCO)年会上展示的肺癌全身治疗早期临床试验中,研究者主观或判断性疗效与毒性(ISJET)报告及1级和2级不良事件合并报告的使用情况。共纳入100项符合条件的研究,中位样本量为43(四分位距29-73),61%为I期试验。88%的研究使用ISJET报告毒性,41%用于报告疗效,仅12%的研究区分1级和2级不良事件。
要点
- 88%的早期肺癌试验使用主观判断性语言报告毒性,41%用于报告疗效。
- 仅12%的研究区分1级和2级不良事件,多数研究合并报告。
- 多数研究(99%)报告任何级别不良事件,96%报告3级不良事件。
核心结论
- 2024年ASCO年会上展示的多数肺癌早期临床试验使用了ISJET,且未区分1级和2级不良事件。
- 有必要采取措施增加客观的疗效和毒性报告语言,并采用更适用的毒性报告方式。
研究设计与样本
- 回顾性分析2024年ASCO年会上展示的针对成人肺癌全身治疗的I期和II期临床试验,至少包含一名肺癌患者。
- 共纳入100项符合条件的研究,中位样本量为43(四分位距29-73),其中61项(61%)为I期试验。
主要发现
- 大多数研究报告了任何级别(99%)和3级(96%)不良事件。
- 仅12%的研究区分了1级和2级不良事件。
- 88%的研究使用ISJET报告毒性,41%的研究使用ISJET报告疗效。
关键数值与推荐
- ISJET根据预设短语如「可耐受」、「可管理」、「可接受」或「良好」进行捕获。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Investigator-assigned Subjective or Judgmental Efficacy and Toxicity (ISJET) reporting represents language used to contextualize efficacy or toxicity data in clinical trials that may be inappropriate or misleading. In addition, pooling of grade 1 and 2 adverse events (AEs) may reflect a practice based on acute chemotherapy treatments rather than the expansion of chronic treatments that are now commonplace for many patients with lung cancer. In this study, we set out to evaluate the use of ISJETs and combined grade 1 and 2 reporting in early phase clinical trials of lung treatments at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. METHODS: Phase I and II clinical trials of systemic treatments in adults with at least one patient with lung cancer presented at the 2024 ASCO Annual Meeting were reviewed. Baseline information and toxicity/efficacy reporting were collected. ISJETs were captured based on predefined phrases such as "tolerable," "manageable," "acceptable," or "favorable." RESULTS: A total of 100 eligible studies were identified. The median sample size was 43 (interquartile range 29-73), and 61 studies (61%) were phase I trials. Most studies reported any-grade (99%) and grade 3 (96%) AEs. Only 12% of the studies distinguished between grade 1 and 2 AEs. ISJETs were used to report toxicity in 88% and efficacy in 41% of the studies, respectively. CONCLUSION: Most early phase lung cancer clinical trials presented at the 2024 ASCO Annual Meeting included ISJETs and did not distinguish between grade 1 and 2 AEs. Initiatives to increase objective efficacy and toxicity reporting language and more fit-for-purpose toxicity reporting are warranted.
引用
- Phillips WJ, Watson AS, Camidge DR, et al. The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments. J Thorac Oncol. 2024. PMID: 39643116. doi:10.1016/j.jtho.2024.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。